Effect of tamsulosin combined with transurethral plasmakinetic resection of prostate on quality of life and sexual function in patients with benign prostatic hyperplasia
-
摘要:
目的 探讨经尿道前列腺等离子电切术(transurethral plasmakinetic resection of prostate,TUPKRP)联合口服坦索罗辛对前列腺增生患者生活质量及性功能的影响。 方法 选取2018年6月—2020年1月期间蚌埠市第三人民医院泌尿外科收治的前列腺增生患者80例,采用随机数字表法分成治疗组(40例)和对照组(40例)。治疗组行TUPKRP联合口服坦索罗辛治疗,对照组仅行TUPKRP治疗。比较2组治疗前、治疗后6个月生活质量[国际前列腺生活质量评分(QOL)、国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、剩余尿量(RUV)、夜间排尿次数)]、性功能[国际勃起功能指数(IIEF-5)]及并发症发生率。 结果 2组治疗前QOL、IPSS、Qmax、RUV及IIEF-5比较差异无统计学意义(均P>0.05);治疗后6个月,治疗组和对照组IIEF-5为(19.35±4.16)分和(17.03±3.52)分,2组QOL、IPSS、Qmax、RUV及IIEF-5均较治疗前改善,治疗组IPSS、QOL、Qmax及IIEF-5评分优于对照组;治疗组夜尿次数[(1.13±0.88)次]少于对照组[(1.65±0.86)次],治疗组并发症发生率低于对照组,差异均有统计学意义(均P<0.05)。 结论 坦索罗辛联合TUPKRP治疗前列腺增生患者有利于改善术后排尿、生活质量及性功能,值得临床推广应用。 Abstract:Objective To investigate the influence of transurethral plasmakinetic resection of prostate (TUPKRP) and1 oral tamsulosin on quality of life and sexual function in patients with benign prostatic hyperplasia (BPH). Methods A total of 80 patients with BPH admitted to The Department of Urology of The Third People's Hospital of Bengbu from June 2018 to January 2020 were selected and divided into treatment group (n=40) and control group (n=40) by random number table method. The treatment group was treated with TUPKRP combined with oral tamsulosin, while the control group was treated with TUPKRP only. Quality of life [International prostate quality of Life Score (QOL), International prostate symptom Score (IPSS), maximum urine flow rate (Qmax), residual urine volume (RUV), times of night urination], sexual function [International erectile function index (IIEF-5)] and incidence of complications were compared between 2 groups before and 6 months after treatment. Results There were no significant differences in QOL, IPSS, Qmax, RUV and IIEF-5 between the two groups before treatment (all P>0.05). Six months after treatment, IIEF-5 of the treatment group and the control group were (19.35±4.16) points and (17.03±3.52) points. QOL, IPSS, Qmax, RUV and IIEF-5 of the two groups were improved compared with that before treatment, IPSS, QOL, Qmax and IIEF-5 of the treatment group were better than that of the control group. Nocturia [(1.13±0.88) times] in the treatment group was less than that in the control group [(1.65±0.86) times], and the incidence of complications in the treatment group was less than that in the control group, with statistical significance (all P < 0.05). Conclusion Tamsulosin combined with TUPKRP is beneficial to improve postoperative urination, quality of life and sexual function in patients with BPH, which is worthy of clinical application. -
表 1 2组BPH患者一般资料比较(x ±s)
组别 例数 年龄(岁) 病程 治疗前夜尿 前列腺重量 术前前列腺特异抗原 (年) (次) (g) (ng/mL) 治疗组 40 71.55±7.10 3.08±1.91 4.03±1.55 69.63±14.68 2.78±1.63 对照组 40 73.55±7.36 2.94±1.81 4.05±1.56 68.35±16.70 2.75±1.47 t值 1.296 0.310 0.076 0.382 0.067 P值 0.203 0.758 0.940 0.704 0.947 表 2 2组BPH患者围手术期指标比较(x ±s)
组别 例数 手术时间 术中出血量 术后膀胱冲洗 术后留置尿 术后住院 切除前列腺组织 (min) (mL) 时间(d) 时间(d) 时间(d) 重量(g) 治疗组 40 57.75±15.06 69.25±27.50 2.15±1.03 3.10±0.71 4.63±0.93 30.43±7.04 对照组 40 59.73±15.50 67.70±27.46 2.10±1.19 3.30±1.04 4.85±1.27 29.85±6.80 t值 1.213 0.582 0.251 1.160 1.026 0.534 P值 0.233 0.564 0.803 0.253 0.311 0.597 表 3 2组BPH患者治疗前及治疗后6个月IPSS、QOL、Qmax、RUV比较(x ±s)
组别 例数 IPSS(分) QOL(分) Qmax(mL/s) RUV(mL) 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 治疗组 40 26.60±3.03 6.25±1.75a 5.05±0.71 1.40±0.67a 7.10±2.46 20.13±2.79a 41.50±22.75 10.38±2.70a 对照组 40 26.73±2.79 8.50±3.00a 5.03±0.80 1.78±0.80a 7.23±2.48 17.05±2.74a 43.05±28.10 10.65±3.77a t值 0.237 3.784 0.138 2.423 0.243 4.725 0.433 0.452 P值 0.814 < 001 0.891 0.020 0.809 0.001 0.667 0.654 注:IPSS为国际前列腺症状评分,QOL为前列腺生活质量评分,Qmax为最大尿流率,RUV为剩余尿量;与同组治疗前比较,aP < 0.05。 表 4 2组BPH患者治疗前及治疗后6个月性功能情况比较
组别 例数 IIEF-5(x±s,分) 勃起功能障碍[例(%)] 治疗前 治疗后 治疗前 治疗后 治疗组 40 17.17±3.97 19.35±4.16b 17(42.50) 12(30.00) 对照组 40 17.80±4.34 17.03±3.52 18(45.00) 21(52.50) 统计量 0.637a 2.745a 0.051c 4.178c P值 0.528 0.009 0.821 0.041 注:a为t值,c为χ2值; 与同组治疗前比较,bP < 0.05。IIEF-5为国际勃起功能指数。 表 5 2组治疗后并发症发生情况比较[例(%)]
组别 例数 继发性血尿 泌尿道感染 术后尿潴留 术后尿失禁 膀胱痉挛 尿道狭窄 总并发症 治疗组 40 1(2.50) 1(2.50) 0(0.00) 1(2.50) 3(7.50) 0(0.00) 6(15.00) 对照组 40 2(5.00) 3(7.50) 2(5.00) 0(0.00) 7(17.50) 1(2.50) 15(37.50) 注:2组并发症发生率比较,χ2=5.230, P=0.022。 -
[1] 罗勇, 唐飞, 冀荣俊, 等. 经尿道前列腺等离子电切术与传统电切术对前列腺增生患者性功能的影响[J]. 中国性科学, 2019, 28(2): 21-23. doi: 10.3969/j.issn.1672-1993.2019.02.005 [2] WANG Z Q, ZHANG J, ZHANG H, et al. Impact on sexual function of plasma button transurethral vapour enucleation versus plasmakinetic resection of the large prostate >90 mL: Results of a prospective, randomized trial[J]. Andrologia, 2020, 52(1): e13390. [3] 章尹岗, 刘文. 经尿道前列腺等离子电切术与经尿道前列腺电切术对良性前列腺增生患者治疗效果及预后性生活质量观察[J]. 中国性科学, 2019, 28(7): 27-30. doi: 10.3969/j.issn.1672-1993.2019.07.005 [4] 覃江, 韦克暖, 蓝杰, 等. 普通电切镜和等离子电切镜在前列腺增生手术治疗中的临床应用[J]. 临床外科杂志, 2020, 28(10): 985-987. doi: 10.3969/j.issn.1005-6483.2020.10.026 [5] 黄克岭, 于艳辉, 高双友. 前列舒通及坦索罗辛联合用药对前列腺增生患者术后功能恢复的干预研究[J]. 实用药物与临床, 2021, 24(6): 525-530. https://www.cnki.com.cn/Article/CJFDTOTAL-LYLC202106012.htm [6] 林斯日, 李本根. 坦洛新对Ⅲ型前列腺炎患者性功能、尿动力学、血清炎症因子的影响研究[J]. 中国性科学, 2020, 29(11): 8-11. doi: 10.3969/j.issn.1672-1993.2020.11.003 [7] 陈星, 陈淑招, 何裕杰, 等. 经尿道前列腺等离子电切术联合坦索罗辛对良性前列腺增生合并慢性前列腺炎患者性功能及生活质量的影响[J]. 慢性病学杂志, 2019, 20(8): 1235-1237. [8] 周浩, 孙超, 李博, 等. 血清前列腺特异性抗原对良性前列腺增生患者前列腺体积的预测价值[J]. 中华全科医学, 2021, 19(1): 46-48. [9] 仇玉萍. 不同社会支持程度对前列腺增生患者术后性功能状态及性生活质量的影响[J]. 中国性科学, 2019, 28(12): 139-142. doi: 10.3969/j.issn.1672-1993.2019.12.037 [10] MUHAMMED M Q, MOHAMMAD A, MOKHTAR M, et al. Association between prostate zonal volume and erectile dysfunction in patients with benign prostatic hyperplasia[J]. Sex Med, 2020, 8(2): 205-213. doi: 10.1016/j.esxm.2020.01.008 [11] 吴华军, 吴军. 盐酸坦索罗辛缓释胶囊联合前列欣胶囊对良性前列腺增生患者疗效及性功能的影响观察[J]. 药品评价, 2019, 16(19): 66-67. doi: 10.3969/j.issn.1672-2809.2019.19.036 [12] 韩琦, 王绍平, 袁欣, 等. 前列腺增生应用经尿道等离子前列腺剜除术和电切术治疗的疗效比较[J]. 黑龙江医药, 2021, 34(3): 682-684. https://www.cnki.com.cn/Article/CJFDTOTAL-HJYY202103079.htm [13] 王德胜, 阴雷, 关超. 保护尿控功能技术在经尿道前列腺等离子剜除术中的应用体会[J]. 中华全科医学, 2019, 17(5): 742-744, 764. [14] 王贻兵, 王侠. 经尿道前列腺剜除术与耻骨上前列腺切除术治疗大体积前列腺增生的效果比较[J]. 中国基层医药, 2019, 26(20): 2467-2470. doi: 10.3760/cma.j.issn.1008-6706.2019.20.008 [15] 陈冬, 孔广起. 经尿道前列腺等离子切除术治疗良性前列腺增生对患者尿道功能及性功能的影响[J]. 中国医刊, 2020, 55(4): 398-401. doi: 10.3969/j.issn.1008-1070.2020.04.016 [16] 王宁华, 苏元华, 董锐, 等. 经尿道等离子双极电切术与开放式前列腺切除术对前列腺增生患者性功能的影响[J]. 中国性科学, 2017, 26(7): 8-11. doi: 10.3969/j.issn.1672-1993.2017.07.002 [17] OTAOLA A H, ÁLVAREZ A M, MOLINA E R, et al. A prospective randomized study comparing bipolar plasmakinetic transurethral resection of the prostate and monopolar transurethral resection of the prostate for the treatment of Benign Prostatic Hyperplasia: efficacy, sexual function, Quality of Life, and complications[J]. Int Braz J Urol, 2021, 47(1): 131-144. doi: 10.1590/s1677-5538.ibju.2019.0766 [18] LIU Z, LI Y W, WU W R, et al. Long-term clinical efficacy and safety profile of transurethral resection of prostate versus plasmakinetic resection of the prostate for benign prostatic hyperplasia[J]. Urology, 2017, 103: 198-203. doi: 10.1016/j.urology.2017.02.006 [19] 黄兴, 罗仪, 訾豪, 等. 前列腺组织切除量及切除率与前列腺等离子双极电切术短期临床疗效的相关性[J]. 现代泌尿外科杂志, 2021, 26(1): 16-20, 74. doi: 10.3969/j.issn.1009-8291.2021.01.004 [20] 郭光, 刘萃龙, 王希友. 合并膀胱逼尿肌无力的前列腺增生患者激光治疗的临床观察[J]. 科学技术与工程, 2021, 21(16): 6632-6636. doi: 10.3969/j.issn.1671-1815.2021.16.014 [21] 张卓. 保留膀胱颈完整性对等离子前列腺剜除术患者术后控尿及性功能的影响[J]. 深圳中西医结合杂志, 2017, 27(6): 90-91. https://www.cnki.com.cn/Article/CJFDTOTAL-SZZX201706045.htm -

计量
- 文章访问数: 440
- HTML全文浏览量: 170
- PDF下载量: 7
- 被引次数: 0